{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T07:48:48Z","timestamp":1794210528462,"version":"4.8.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T00:00:00Z","timestamp":1689552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T00:00:00Z","timestamp":1689552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","award":["Takeda Pharmaceuticals U.S.A."],"award-info":[{"award-number":["Takeda Pharmaceuticals U.S.A."]}],"id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Metachromatic leukodystrophy (MLD) is a rare lysosomal storage disease caused by deficient activity of arylsulfatase A (ASA). Treatment options for patients are limited; gene therapy based on haematopoietic stem cell transplantation is the only approved treatment for some subtypes of MLD. Any therapeutic benefit of treatments must be meaningful for patients and their families. We evaluated the clinical meaningfulness of slowing the decline in gross motor function as measured by the Gross Motor Function Classification in MLD (GMFC-MLD) from the caregiver perspective via semi-structured telephone interviews with caregivers of children with late-infantile MLD. We also evaluated the perceived significance of declines in communication abilities measured by the Expressive Language Function Classification in MLD (ELFC-MLD). This work could help to inform the endpoints of a phase 2 clinical trial (NCT03771898) assessing the efficacy of intrathecal recombinant human ASA in MLD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Twelve caregivers were recruited, reporting on 12 children with MLD. Children had a mean age of 6.1 years; mean age at symptom onset was 17.6 months. Most children (10\/12) progressed from walking without support (categories 0\u20131) to a loss of locomotion (categories 5\u20136) in \u2264\u20092 years. Caregivers felt that GMFC-MLD and ELFC-MLD accurately described motor and language declines in their children, respectively. Most caregivers (10\/12) reported that the idea of delaying disease progression would be meaningful. Further, a slowing of motor function decline in GMFC-MLD, from category 1 to category 3 or from category 2 to category 4 over 2 years, was seen as meaningful by all caregivers asked; however, only 3\/12 caregivers reported that delayed decline would be meaningful if baseline category was \u2265\u20093. Caregivers also reported that delaying expressive language decline at any level that did not indicate a complete loss of expressive language (indicated by categories 1\u20133) would be meaningful.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Caregivers of children with MLD felt that a delayed decline in gross motor function, as assessed by the GMFC-MLD, would be meaningful, supporting the selection of primary and secondary endpoints for the phase 2 clinical trial. Communication abilities were another area of significance for consideration in future clinical trial design.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s41687-023-00595-7","type":"journal-article","created":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T08:01:54Z","timestamp":1689580914000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Evaluating meaningful changes in physical functioning and cognitive declines in metachromatic leukodystrophy: a caregiver interview study"],"prefix":"10.1186","volume":"7","author":[{"given":"Susan","family":"Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimanee","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothy","family":"Romanus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,17]]},"reference":[{"key":"595_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1651-2227.2008.00648.x","volume":"97","author":"V Gieselmann","year":"2008","unstructured":"Gieselmann V (2008) Metachromatic leukodystrophy: genetics, pathogenesis and therapeutic options. Acta Paediatr 97:15\u201321. https:\/\/doi.org\/10.1111\/j.1651-2227.2008.00648.x","journal-title":"Acta Paediatr"},{"key":"595_CR2","doi-asserted-by":"publisher","DOI":"10.1036\/ommbid.179","volume-title":"Scriver\u2019s online metabolic and molecular bases of inherited disease","author":"V Gieselmann","year":"2018","unstructured":"Gieselmann V, Kr\u00e4geloh-Mann I (2018) Metachromatic leukodystrophy. Scriver\u2019s online metabolic and molecular bases of inherited disease. McGraw-Hill, New York. https:\/\/ommbid.mhmedical.com\/content.aspx?bookid=2709&sectionid=225546629"},{"key":"595_CR3","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.beem.2014.10.001","volume":"29","author":"DF van Rappard","year":"2015","unstructured":"van Rappard DF, Boelens JJ, Wolf NI (2015) Metachromatic leukodystrophy: disease spectrum and approaches for treatment. Best Pract Res Clin Endocrinol Metab 29:261\u2013273. https:\/\/doi.org\/10.1016\/j.beem.2014.10.001","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"595_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1055\/s-0030-1253412","volume":"41","author":"V Gieselmann","year":"2010","unstructured":"Gieselmann V, Krageloh-Mann I (2010) Metachromatic leukodystrophy - an update. Neuropediatrics 41:1\u20136. https:\/\/doi.org\/10.1055\/s-0030-1253412","journal-title":"Neuropediatrics"},{"key":"595_CR5","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/j.1469-8749.2011.04028.x","volume":"53","author":"C Kehrer","year":"2011","unstructured":"Kehrer C, Blumenstock G, Gieselmann V, Kr\u00e4geloh-Mann I (2011) The natural course of gross motor deterioration in metachromatic leukodystrophy. Dev Med Child Neurol 53:850\u2013855. https:\/\/doi.org\/10.1111\/j.1469-8749.2011.04028.x","journal-title":"Dev Med Child Neurol"},{"key":"595_CR6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1750-1172-9-18","volume":"9","author":"C Kehrer","year":"2014","unstructured":"Kehrer C, Groeschel S, Kustermann-Kuhn B, B\u00fcrger F, K\u00f6hler W, Kohlsch\u00fctter A, Bley A, Steinfeld R, Gieselmann V, Kr\u00e4geloh-Mann I (2014) Language and cognition in children with metachromatic leukodystrophy: onset and natural course in a nationwide cohort. Orphanet J Rare Dis 9:18. https:\/\/doi.org\/10.1186\/1750-1172-9-18","journal-title":"Orphanet J Rare Dis"},{"key":"595_CR7","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13023-019-1060-2","volume":"14","author":"M Harrington","year":"2019","unstructured":"Harrington M, Whalley D, Twiss J, Rushton R, Martin S, Huynh L, Yang H (2019) Insights into the natural history of metachromatic leukodystrophy from interviews with caregivers. Orphanet J Rare Dis 14:89. https:\/\/doi.org\/10.1186\/s13023-019-1060-2","journal-title":"Orphanet J Rare Dis"},{"key":"595_CR8","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/s0140-6736(16)30450-0","volume":"388","author":"I Krageloh-Mann","year":"2016","unstructured":"Krageloh-Mann I, Groeschel S (2016) Therapies of lysosomal storage disorders targeting the brain. Lancet 388:440\u2013442. https:\/\/doi.org\/10.1016\/s0140-6736(16)30450-0","journal-title":"Lancet"},{"key":"595_CR9","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.ymgme.2020.07.002","volume":"131","author":"C\u00cd Dali","year":"2020","unstructured":"Dali C, Sevin C, Kr\u00e4geloh-Mann I, Giugliani R, Sakai N, Wu J, Wasilewski M (2020) Safety of intrathecal delivery of recombinant human arylsulfatase A in children with metachromatic leukodystrophy: results from a phase 1\/2 clinical trial. Mol Genet Metab 131:235\u2013244. https:\/\/doi.org\/10.1016\/j.ymgme.2020.07.002","journal-title":"Mol Genet Metab"},{"key":"595_CR10","unstructured":"European Medicines Agency, https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/libmeldy. Accessed 14 March 2022"},{"key":"595_CR11","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/s0140-6736(21)02017-1","volume":"399","author":"F Fumagalli","year":"2022","unstructured":"Fumagalli F, Calbi V, Natali Sora MG, Sessa M, Baldoli C, Rancoita PMV, Ciotti F, Sarzana M, Fraschini M, Zambon AA, Acquati S, Redaelli D, Attanasio V, Miglietta S, De Mattia F, Barzaghi F, Ferrua F, Migliavacca M, Tucci F, Gallo V, Del Carro U, Canale S, Spiga I, Lorioli L, Recupero S, Fratini ES, Morena F, Silvani P, Calvi MR, Facchini M, Locatelli S, Corti A, Zancan S, Antonioli G, Farinelli G, Gabaldo M, Garcia-Segovia J, Schwab LC, Downey GF, Filippi M, Cicalese MP, Martino S, Di Serio C, Ciceri F, Bernardo ME, Naldini L, Biffi A, Aiuti A (2022) Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1\/2 trial and expanded access. Lancet 399:372\u2013383. https:\/\/doi.org\/10.1016\/s0140-6736(21)02017-1","journal-title":"Lancet"},{"key":"595_CR12","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1177\/0883073816656401","volume":"31","author":"FS Eichler","year":"2016","unstructured":"Eichler FS, Cox TM, Crombez E, Dali CI, Kohlschutter A (2016) Metachromatic leukodystrophy: an assessment of disease burden. J Child Neurol 31:1457\u20131463. https:\/\/doi.org\/10.1177\/0883073816656401","journal-title":"J Child Neurol"},{"key":"595_CR13","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3389\/fmed.2018.00230","volume":"5","author":"D Haerry","year":"2018","unstructured":"Haerry D, Landgraf C, Warner K, Hunter A, Klingmann I, May M, See W (2018) EUPATI and patients in medicines research and development: Guidance for patient involvement in regulatory processes. Front Med 5:230. https:\/\/doi.org\/10.3389\/fmed.2018.00230","journal-title":"Front Med"},{"key":"595_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/MLR.0000000000000273","volume":"53","author":"EM Perfetto","year":"2015","unstructured":"Perfetto EM, Burke L, Oehrlein EM, Epstein RS (2015) Patient-focused drug development: a new direction for collaboration. Med Care 53:9\u201317. https:\/\/doi.org\/10.1097\/MLR.0000000000000273","journal-title":"Med Care"},{"key":"595_CR15","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.jval.2016.11.014","volume":"20","author":"EM Perfetto","year":"2017","unstructured":"Perfetto EM, Oehrlein EM, Boutin M, Reid S, Gascho E (2017) Value to whom? The patient voice in the value discussion. Value Health 20:286\u2013291. https:\/\/doi.org\/10.1016\/j.jval.2016.11.014","journal-title":"Value Health"},{"key":"595_CR16","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s12325-019-00920-x","volume":"36","author":"MG Contesse","year":"2019","unstructured":"Contesse MG, Valentine JE, Wall TE, Leffler MG (2019) The case for the use of patient and caregiver perception of change assessments in rare disease clinical trials: a methodologic overview. Adv Ther 36:997\u20131010. https:\/\/doi.org\/10.1007\/s12325-019-00920-x","journal-title":"Adv Ther"},{"key":"595_CR17","unstructured":"ClinicalTrials.gov, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03771898. Accessed 14 March 2022"},{"key":"595_CR18","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/j.1469-8749.2010.03821.x","volume":"53","author":"C Kehrer","year":"2011","unstructured":"Kehrer C, Blumenstock G, Raabe C, Kr\u00e4geloh-Mann I (2011) Development and reliability of a classification system for gross motor function in children with metachromatic leucodystrophy. Dev Med Child Neurol 53:156\u2013160. https:\/\/doi.org\/10.1111\/j.1469-8749.2010.03821.x","journal-title":"Dev Med Child Neurol"},{"key":"595_CR19","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13023-015-0313-y","volume":"10","author":"AA Boucher","year":"2015","unstructured":"Boucher AA, Miller W, Shanley R, Ziegler R, Lund T, Raymond G, Orchard PJ (2015) Long-term outcomes after allogeneic hematopoietic stem cell transplantation for metachromatic leukodystrophy: the largest single-institution cohort report. Orphanet J Rare Dis 10:94. https:\/\/doi.org\/10.1186\/s13023-015-0313-y","journal-title":"Orphanet J Rare Dis"},{"key":"595_CR20","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/1750-1172-8-101","volume":"8","author":"M Raluy-Callado","year":"2013","unstructured":"Raluy-Callado M, Chen W-H, Whiteman DAH, Fang J, Wiklund I (2013) The impact of Hunter syndrome (mucopolysaccharidosis type II) on health-related quality of life. Orphanet J Rare Dis 8:101. https:\/\/doi.org\/10.1186\/1750-1172-8-101","journal-title":"Orphanet J Rare Dis"},{"key":"595_CR21","doi-asserted-by":"publisher","first-page":"e255","DOI":"10.1212\/wnl.0000000000011047","volume":"96","author":"C Kehrer","year":"2021","unstructured":"Kehrer C, Elg\u00fcn S, Raabe C, B\u00f6hringer J, Beck-W\u00f6dl S, Bevot A, Kaiser N, Sch\u00f6ls L, Kr\u00e4geloh-Mann I, Groeschel S (2021) Association of age at onset and first symptoms with disease progression in patients with metachromatic leukodystrophy. Neurology 96:e255\u2013e266. https:\/\/doi.org\/10.1212\/wnl.0000000000011047","journal-title":"Neurology"},{"key":"595_CR22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s41687-018-0041-x","volume":"2","author":"TM Brown","year":"2018","unstructured":"Brown TM, Martin S, Fehnel SE, Deal LS (2018) Development of the impact of juvenile metachromatic leukodystrophy on physical activities scale. J Patient Rep Outcomes 2:15. https:\/\/doi.org\/10.1186\/s41687-018-0041-x","journal-title":"J Patient Rep Outcomes"},{"key":"595_CR23","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s13023-021-01828-y","volume":"16","author":"L Ammann-Schnell","year":"2021","unstructured":"Ammann-Schnell L, Groeschel S, Kehrer C, Fr\u00f6lich S, Kr\u00e4geloh-Mann I (2021) The impact of severe rare chronic neurological disease in childhood on the quality of life of families\u2014a study on MLD and PCH2. Orphanet J Rare Dis 16:211. https:\/\/doi.org\/10.1186\/s13023-021-01828-y","journal-title":"Orphanet J Rare Dis"},{"key":"595_CR24","doi-asserted-by":"publisher","first-page":"1233158","DOI":"10.1126\/science.1233158","volume":"341","author":"A Biffi","year":"2013","unstructured":"Biffi A, Montini E, Lorioli L, Cesani M, Fumagalli F, Plati T, Baldoli C, Martino S, Calabria A, Canale S, Benedicenti F, Vallanti G, Biasco L, Leo S, Kabbara N, Zanetti G, Rizzo WB, Mehta NAL, Cicalese MP, Casiraghi M, Boelens JJ, Del Carro U, Dow DJ, Schmidt M, Assanelli A, Neduva V, Di Serio C, Stupka E, Gardner J, Von Kalle C, Bordignon C, Ciceri F, Rovelli A, Roncarolo MG, Aiuti A, Sessa M, Naldini L (2013) Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 341:1233158. https:\/\/doi.org\/10.1126\/science.1233158","journal-title":"Science"},{"key":"595_CR25","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S0140-6736(16)30374-9","volume":"388","author":"M Sessa","year":"2016","unstructured":"Sessa M, Lorioli L, Fumagalli F, Acquati S, Redaelli D, Baldoli C, Canale S, Lopez ID, Morena F, Calabria A, Fiori R, Silvani P, Rancoita PM, Gabaldo M, Benedicenti F, Antonioli G, Assanelli A, Cicalese MP, Del Carro U, Sora MG, Martino S, Quattrini A, Montini E, Di Serio C, Ciceri F, Roncarolo MG, Aiuti A, Naldini L, Biffi A (2016) Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1\/2 trial. Lancet 388:476\u2013487. https:\/\/doi.org\/10.1016\/S0140-6736(16)30374-9","journal-title":"Lancet"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-023-00595-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-023-00595-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-023-00595-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T08:06:18Z","timestamp":1689581178000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpro.springeropen.com\/articles\/10.1186\/s41687-023-00595-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,17]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["595"],"URL":"https:\/\/doi.org\/10.1186\/s41687-023-00595-7","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,17]]},"assertion":[{"value":"10 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was reviewed and deemed exempt by RTI International\u2019s institutional review board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent for study participation and publication of the study results was obtained from the parents of the patients. A copy of the consent form is available for review by the Editor of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SM and NH are employees of RTI Health Solutions. DR is full-time employee and stockholder of Takeda.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"70"}}